Table 3.31 Association of estimates of omega-3 fatty acids with cardiac death in prospective cohort studies

Author Year LocationNDuration (year)Dietary AssessmentResultsTrend P-valueOverall effectQualityApplicability
Estimated omega-3 fatty acid consumption
Relative risk (unless stated otherwise)
Pietinen 1997 Finland219306.1FFQALA0.91.21.51.92.5g/dNS0AGEN II
ABCC 1.00.940.981.030.99
EPA+DHA0.20.30.40.50.8g/d
1.00.941.01.11.3
Dolecek1992 US625010.5Multiple 24-hr recallALA0.871.31.61.92.8g/dNS 0.01+ +AGEN II
MRFIT 1.00.980.570.980.68
EPA+DHA00.0090.0460.150.66g/d
1.01.10.910.880.60
1

Adjusted results are presented here when reported in original study. See evidence tables for details.

2

Trend for inverse association. Up arrow indicates a statistically significant positive association (worse outcome).

*

Statistically significant p<0.05; numerical p-value reported for p<0.1.

Study acronyms:

ABCC = Alpha-Tocopherol Beta-Carotene Cancer Prevention

ADVENTIST = Adventist Health Study

CHS = Cardiovascular Health Study

HPS = Health Professionals Study

MRFIT = Multiple Risk Factor Intervention Study

NHANES = National Health and Nutrition Examination Study

NHS = Nurses' Health Study

PHS = Physicians' Health Study

WES = Western Electric Company Study

From: Summary Tables

Cover of Effects of Omega-3 Fatty Acids on Cardiovascular Disease
Effects of Omega-3 Fatty Acids on Cardiovascular Disease.
Evidence Reports/Technology Assessments, No. 94.
Wang C, Chung M, Lichtenstein A, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.